Multiple Chinese Pharma Companies Secure Over RMB 100 Million in Financing to Accelerate Innovative Drug Development

　　【Pharmaceutical Network Industry Dynamics】Recently, GDP ClinPlus, a provider of clinical research services for pharmaceutical products, has completed a B+ round of financing worth tens of millions of yuan, led by Taikun Fund with participation from several well-known institutions. This round of financing will further strengthen the company’s foundation, improve service efficiency, connect global resources, and integrate "the professionalism of Chinese services" with "the integration capability of international resources," shortening the path for innovative drugs from the laboratory to clinical trials.
 

It is reported that GDP ClinPlus is a CRO company with 22 years of experience in clinical research services. The company has participated in over 2,200 clinical projects and supported more than 210 product approvals in China, the United States, and Europe. It serves over 500 pharmaceutical, biotechnology, and medical device companies globally, covering Phase I to IV clinical trials, data management and statistics, regulatory affairs, and other fields. With a mature quality management system, efficient project execution capabilities, and continuous investment in technology, the company has been focusing on enhancing its service capabilities in the cell and gene therapy (CGT) field in recent years. It has supported over 80 CGT-related clinical studies, covering cutting-edge technologies such as small nucleic acids, CAR-T, RNA, stem cells, and gene therapy. Additionally, the company has deep expertise in oncology and metabolic diseases, having completed over 500 oncology studies and demonstrated outstanding execution in multiple early-stage and pivotal registration studies.
 

Recently, in addition to GDP ClinPlus, a large number of pharmaceutical companies have completed financing, with amounts ranging from tens of millions to hundreds of millions of yuan. For instance, on August 5th, Zenitar, a drug research and development company driven by structural biology and artificial intelligence, completed a nearly 400-million-yuan B+ round of financing. This round was led by Qiming Venture Partners, with participation from Gaorong Capital, Jiyuan Capital, Qi Ji Investment, 5Y Capital, Zhongyuan Investment, and Sichuan Biomedical Industry Group. Zenitar focuses on the research and development of innovative drugs for cancer, autoimmune diseases, and cytokine storms caused by COVID-19. Currently, its R&D pipeline covers various fields including solid tumors and hematological malignancies.
 

Next-Generation Protein Degradation New Drug R&D Platform Artix Bio Announces Completion of Series A Financing on August 1st, Jointly Invested by Shanghai Biomedical Innovation and Transformation Fund under Shanghai Industrial Capital and Sanfu Fund. The funds raised will be used for the improvement and optimization of novel molecular glue drugs and to advance preclinical research of candidate molecules in Parkinson's disease.
 

DARWIN BIOTECH, a provider of cell biotechnology services in China, announced on July 31 the completion of its C-round financing, with a total amount exceeding 200 million RMB. This round of investment was exclusively participated by Tsinghua Holdings Ginkgo Venture Capital. As one of the first biotech transformation enterprises in China to focus on clinical research, DARWIN BIOTECH has consistently concentrated on patent innovation in cell biotechnology and multidisciplinary integration, promoting the upgrading of medical science and technology as well as industrial implementation. This financing will help deepen innovative technology research and development, accelerate the transformation of achievements across multiple fields, and further consolidate its position in the industry.
 

Prucon Biotech Announces Completion of Nearly RMB 10 Million Angel Round Financing on July 29The funds raised will mainly be used for the development of Class I veterinary drugs for feline hypertrophic cardiomyopathy. Prucon Biotech focuses on innovative drug research, development, and sales for metabolic diseases such as pet heart disease, cancer, and kidney disease. The company has established a high-level R&D team, an independent R&D system, and technological platforms. Through strategic cooperation with animal clinical institutions, the company has screened out a series of candidate compounds with clinical efficacy.
 

Moreover, since July, companies such as Pilot Bio, Orange Sail Pharma, Now Biological, and Uni-Pharm have announced the completion of new rounds of financing, with much of the funding to be used for product development.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.